Clinical Trials Sponsored by Ambryx Biotechnology

Total 1096 results

Ambryx Biotechnology
Texas A&M University; Baylor University

Completed

Clinical Safety of a Novel Milk Protein Peptide

Drug Safety

United States
Ambrx, Inc.

Recruiting

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

HER2 Positive Metastatic Breast Cancer

United States, Korea, Republic of, France, Australia
Ambrx, Inc.

Recruiting

ARX517 as Monotherapy and in Combination Regimens in Subjects With Metastatic Castration-resistant Prostate Cancer (ARX517)

Prostate Cancer

United States
Ambrx, Inc.

Completed

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Breast Neoplasms | Solid Tumors | Gastric Neoplasm

United States, Australia
Ambrx, Inc.

Withdrawn

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

HER2 Mutation-Related Tumors | HER2 Amplified Solid Tumors

United States
Ambry Genetics

Completed

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

Breast Cancer Risk

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Australia
Grit Biotechnology

Recruiting

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Adult

China
AVB Biotechnology

Recruiting

Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease (DoBiC-19)

Virus Diseases | COVID-19 | COVID-19 Pneumonia

Turkey
Grit Biotechnology

Recruiting

TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Avecho Biotechnology

Not yet recruiting

Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia

Insomnia
EVIVE Biotechnology

Withdrawn

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

COVID-19 Pneumonia
EVIVE Biotechnology

Completed

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Cellect Biotechnology

Unknown

Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

Acute Lymphoblastic Leukemia (ALL) | Hodgkin Lymphoma, Adult | Acute Myelogenous Leukemia (AML) | Non Hodgkin Lymphoma (NHL)

Israel
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Australia
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Melanoma

Australia, United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Study of PI-88 in Patients With Advanced Melanoma

Melanoma

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Terminated

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection (PATRON)

Cancer | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, Taiwan, Hong Kong, China
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Carcinoma, Hepatocellular

Taiwan
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) (GLEAM)

Systemic Lupus Erythematosus | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Lupus Erythematosus | SLE (Systemic Lupus) | Granulomatous Polyangiitis

United States
Grit Biotechnology

Recruiting

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Adult | Gynecological Tumors

China
Grit Biotechnology

Recruiting

GT201 Injection For The Treatment Of Advanced Solid Tumors

Solid Tumor, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

Solid Tumor | Adult | GT316

China
Grit Biotechnology

Recruiting

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Adult

China
Grit Biotechnology

Recruiting

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Solid Tumor

China
DynamiCure Biotechnology

Terminated

DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
EVIVE Biotechnology

Completed

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
EVIVE Biotechnology

Completed

Trial to Compare the Efficacy and Safety of F-627 and GRAN® (F-627)

Breast Cancer

China
Sana Biotechnology

Not yet recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma
Grit Biotechnology

Not yet recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Adult

China
Grit Biotechnology

Not yet recruiting

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma

HNSCC | Adults

China
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Australia
DynamiCure Biotechnology

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, Australia
Grit Biotechnology

Recruiting

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

Solid Tumors, Adult

China
Grit Biotechnology

Recruiting

Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors (GT201)

Solid Tumor

China
Maia Biotechnology

Recruiting

THIO Sequenced With Cemiplimab in Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

Poland, Australia, Bulgaria, Hungary
EVIVE Biotechnology

Terminated

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

Covid19

United States
Cellect Biotechnology

Unknown

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

Hematological Malignancies

Israel
EVIVE Biotechnology

Completed

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Amryt Research Limited

Completed

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE)

Epidermolysis Bullosa

United States, Spain, Israel, Australia, France, Denmark, Switzerland, Italy, Hong Kong, Argentina, Austria, Brazil, Chile, Colombia, Czechia, Georgia, Germany, Greece, Hungary, Ireland, Romania, Russian Federation, Serbia, Singapore, U... and more
Amylyx Pharmaceuticals Inc.

Recruiting

AMX0035 in Adult Patients With Wolfram Syndrome

Wolfram Syndrome

United States
Amylyx Pharmaceuticals Inc.

Completed

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Amylyx Pharmaceuticals Inc.

Enrolling by invitation

Extension Study Evaluating The Safety And Tolerability of AMX0035

Amyotrophic Lateral Sclerosis

Belgium, Spain, Netherlands, United Kingdom, Sweden, France, Germany, Ireland, Italy, Poland, Portugal
Amylyx Pharmaceuticals Inc.

Active, not recruiting

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix)

Amyotrophic Lateral Sclerosis

United States, Belgium, Spain, Netherlands, United Kingdom, Germany, Sweden, France, Ireland, Italy, Poland, Portugal
Amylyx Pharmaceuticals Inc.

Approved for marketing

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Amyotrophic Lateral Sclerosis

United States, Puerto Rico
Amylyx Pharmaceuticals Inc.

Recruiting

AMX0035 and Progressive Supranuclear Palsy (ORION)

Neurodegenerative Diseases | Progressive Supranuclear Palsy | Atypical Parkinsonism | PSP

United States
Amylyx Pharmaceuticals Inc.

Active, not recruiting

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

ALS

United States
Meryx, Inc.

Recruiting

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States
Amryt Pharma

Recruiting

LOWER: Lomitapide Observational Worldwide Evaluation Registry (LOWER)

Homozygous Familial Hypercholesterolemia

Italy, United States, Argentina, Canada, France, Greece, Netherlands, United Kingdom

Clinical Trials Sponsored by Ambryx Biotechnology

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations